Reallocation in the portfolio:
Out went $AFX (+0.2%)
New in $ASML (-1.59%)
The decision was not easy, as I am still convinced of Meditec, but unfortunately the market simply sees things differently at the moment.
I see more upside for ASML as a shovel seller and more downside for Meditec with the possible tariff war between USA - Europe - China ( Asia accounts for a third of sales in 2023 according to Trading View )
Meditec remains on the watch while I wait for the quarterly figures on 11.12